Scroll down


Would you like to explore the possibilities for obtaining a license for this technology? You can contact our licensing team by mail. Would you like to know more about our technologies and licensing possibilities? Visit our webpage about Licensing KeyGene’s proprietary technologies.


The invention provides for a method for targeted alteration of DNA using a newly designed (donor) oligonucleotide resulting in more efficient Targeted Nucleotide Exchange (TNE) or Oligonucleotide Directed Mutagenesis (ODM).


Genome editing technologies are rapidly emerging. Many targeted genome editing technologies require the (co-)transfection of single stranded oligonucleotides designed to direct the repair of a mutation of interest. The patented genome editing technology makes use of an oligonucleotide that is capable of hybridizing to the DNA and that has the mismatch at most two nucleotides of its 3′ end, resulting in efficient TNE.


Efficient targeted genome editing technologies are important research tools in gene validation and may be used for introduction of new traits in crop germplasm. The more effective genome editing technology of the present invention contributes thereto.


Click on the link below for an overview of the patent family in the European Patent Register:


Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.